This site is intended for health professionals only
Thursday 27 June 2019
Share |

Topic: Pain management

June 6, 2018
First monoclonal antibody therapy for prevention of migraine

The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Aimovig (erenumab).
 
The EMA’s Committee for Medicinal Products for Human Use (CHMP) said the drug was the first human monoclonal antibody therapy for preventing migraine.
 
Aimovig, produced by Novartis Europharm, belongs to a new class of medicines that work by blocking the activity of calcitonin gene-related peptide (CGRP) – a molecule that is involved in migraine attacks.
 

April 19, 2018
<p>Novartis announces Aimovig&trade; could be an effective preventive treatment option for episodic migraine patients where previous treatments have failed</p>

A treatment for patients with episodic migraines could at least halve the number of days they experience them every month, researchers have found.

 

This April, healthcare organisation Novartis announced the results of a study that looked specifically at episodic migraine patients who had previously failed 2 to 4 preventive treatments, due to lack of efficacy and/or intolerable side effects.

 

January 29, 2018
A study led by the University of Warwick in the UK could help thousands of headache sufferers

Researchers at Warwick Medical School are investigating whether a new education and self-management programme will help improve quality of life for people living with chronic headaches.
 

The study, Chronic Headache Education and Self-management Study (CHESS), is funded by the National Institute for Health Research, and is led by Professor Martin Underwood.  
 

January 23, 2018
Randomised controlled trial to compare two different treatments and aims to reduce reliance on strong painkillers

The University of Warwick in the UK is starting a trial to improve the lives of long-term strong painkiller users.

 

Researchers from the University’s Warwick Medical School and The James Cook University Hospital, Middlesbrough, have developed a support programme that they hope will help people with long term pain reduce their dependency on strong pain killers (opioids) and improve their quality of life.

 

January 23, 2018
The trial met its primary endpoint of percentage of patients on erenumab (AMG 334) achieving at least a 50% reduction of migraine days versus placebo, and all secondary endpoints

Novartis has announced positive results from the Phase IIIb LIBERTY study assessing the efficacy and safety of erenumab (AMG 334) 140mg in patients with episodic migraine who had experienced two to four previous preventive treatment failures, due to lack of efficacy or intolerable side effects.

 

November 30, 2017
Patients with episodic migraine taking erenumab reported significant and meaningful benefits over six months, with reduced migraine days and acute medication use

Novartis has announced that the New England Journal of Medicine (NEJM) published positive results from the six-month Phase III STRIVE study evaluating erenumab in the prevention of episodic migraine (defined in STRIVE as 4 to 14 migraine days per month).1

 

March 1, 2016
Moventig is the first once-daily, oral peripherally acting mu-opioid receptor antagonist approved in Europe for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s)

ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co Ltd, and AstraZeneca announced that they have entered into an agreement for ProStrakan to acquire the rights to Moventig® (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein. Moventig is the first once-daily, oral peripherally acting mu-opioid receptor antagonist (PAMORA) approved in Europe for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
 

October 20, 2015
A study has provided important insights into the analgesic effects of prolonged release oxycodone/naloxone for Parkinson’s disease patients with chronic, severe pain

A study published in The Lancet Neurology has provided important insights into the analgesic effects of prolonged release oxycodone/naloxone (OXN PR) for Parkinson’s disease patients with chronic, severe pain. (1) The primary endpoint of improved average 24-hour pain score with OXN PR versus placebo at week 16 was not met (p=0.058), however assessments at other time points as well as secondary endpoint data indicate some potentially positive treatment effects with OXN PR. (1)
 

 

July 14, 2015
Futura Medical has developed a "new generation” of topical pain relief with two products that target more active ingredients directly to the point of pain
March 19, 2015
The International Society of Nephrology (ISN) will present the findings of a new global study on Acute Kidney Injury (AKI), seen by experts as a key step forward in their efforts to eliminate preventable deaths from the condition by 2025 (0by25).

The International Society of Nephrology (ISN) will present the findings of a new global study on Acute Kidney Injury (AKI), seen by experts as a key step forward in their efforts to eliminate preventable deaths from the condition by 2025 (0by25).

AKI is a worldwide problem, killing affected patients who have no means to reach appropriate therapy in developing countries, and who could be saved with as little as $150.

February 16, 2015
Local development and promotion of evidence-based treatment pathways for chronic pain can improve patient access to evidence-based medicines and avoid inappropriate use of healthcare resources

 

March 24, 2014
A study reported (13TH March 2014) in the International Headache Society’s official journal Cephalalgia found that the use of electroCore’s non invasive vagus nerve stimulation therapy (nVNS) may be an effective and well tolerated treatment for migraine in certain patients.

 

January 15, 2014
BD (Becton, Dickinson and Company), a leading global medical technology company, has announced that following the approval of the BD Saf-T-Intima™ Safety Integrated IV Catheter System for use in subcutaneous infusion therapies that it will be collaborating with pain management and palliative care infusion pump specialists, CME Medical, to increase coverage in the UK and Ireland and to provide expanded specialist support to its growing Saf-T-Intima™ customer base.

 

October 1, 2013
Recent reports have sounded alarms about the inappropriate use of prescription opioids but pharmacists should lead intelligent and sensitive education about these essential drugs

 

July 25, 2013
BD (Becton, Dickinson and Company), a leading global medical technology company, announces the approval of the BD Saf-T-Intima™ Safety Integrated IV Catheter System for use in subcutaneous infusion therapies in Europe.
BD (Becton, Dickinson and Company), a leading global medical technology company, announces the approval of the BD Saf-T-Intima™ Safety Integrated IV Catheter System for use in subcutaneous infusion therapies in Europe.
 
Subcutaneous infusion is increasingly and widely used for therapies such as rehydration, post-operative pain management, palliative care and paediatric care. It provides an affordable, effective, and less invasive alternative to the established intravenous route.
June 7, 2013
The article discusses the importance of pain assessment to identify the cause and impact of pain and pharmacological pain management strategies in the context of chronic kidney disease

teaser

May 8, 2013
In a poster presented at the CONy[1] meeting in Istanbul, by Dr. Alan Rapoport of the David Geffen School of Medicine at UCLA, the rapidly advancing field of neuromodulation was reviewed for its promise as a possible treatment for both migraine and cluster headaches.

teaser

March 12, 2013
The recent approval of a dermal capsaicin 8% patch with a long duration of action invites an examination of recent advances in the understanding of its therapeutic potential in neuropathic pain

teaser

March 12, 2013
Clinical trials of oxycodone

teaser

October 12, 2012
Chronic pain has reached truly epidemic proportions in Europe. One in five Europeans suffers from pain that has been occurring regularly for three months or longer; one in eleven, suffers from pain daily.

teaser

October 9, 2012
One in five people in Europe live with pain, for one in eleven it is a fact of daily life.

teaser

October 4, 2012
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, has announced publication of results from the first large-scale study of peripheral nerve stimulation (PNS) of the occipital nerves in patients suffering from chronic migraine. The study results, published online by Cephalalgia the journal of the International Headache Society, show a significant reduction in pain, headache days and migraine-related disability.

teaser

September 18, 2012
The introduction of multidisciplinary acute pain services, taking responsibility for co-ordinating all aspects of training and guideline development, have resulted in improvements in the overall standards of post-operative pain management

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine